GlobalData believes that either an FDA decision to remove the drug from the...
Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is the first and the only approved antibody-drug conjugate for the treatment of advanced triple-negative breast cancer (TNBC) in adult patients.
TUKYSA™ (tucatinib) for the treatment of HER2-Positive Breast Cancer
TUKYSA™ (tucatinib) is the first HER-2 tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer.
Sojournix starts clinical trial of SJX-653 for menopausal hot flashes
Clinical-stage biopharmaceutical firm Sojournix has started a Phase II trial to evaluate the efficacy of SJX-653, a once-daily regimen for moderate to severe vasomotor symptoms (VMS), hot flashes, and night sweats associated with the menopause.
US trial evaluates osteoporosis drug to prevent breast cancer
Researchers at Washington University School of Medicine in St Louis, US, are evaluating osteoporosis drug denosumab in a Phase II clinical trial to prevent breast cancer in women.
Low-dose aspirin to reduce preterm delivery in first-time mothers
A daily low-dose aspirin helped first-time mothers lower their chances of delivering a baby too soon in a new clinical trial funded by the National Institutes of Health (NIH).
Overview of triple-negative breast cancer clinical trials
TNBC is a form of breast cancer that is not stimulated by estrogen, progesterone or the HER2 protein.
FDA faces conundrum over future of AMAG’s Makena following drug withdrawal
GlobalData believes that either an FDA decision to remove the drug from the market or a request for a new confirmatory trial will have significant implications for patients and the company.
ObsEva plans to halt clinical programme of IVF nolasiban drug
Biopharmaceutical firm ObsEva will end the current clinical development programme of nolasiban IVF after the drug failed in the Phase III IMPLANT 4 clinical trial in Europe.
Which companies are leading late-stage development in the female infertility space?
While GlobalData projects the female infertility drugs market to grow through 2028 across seven major markets, this growth will be restricted by the sparse pipeline and the limited number of innovative drugs under development.
Novartis still hoping for Entresto success in heart failure with preserved ejection fraction
At ESC 2019, Novartis gave insight into the unsuccessful results of the PARAGON-HF trial for heart failure with preserved ejection fraction (HF-PEF).